ProCE Banner Activity

SELECT-CHOICE: Upadacitinib vs Abatacept in Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to bDMARDs

Slideset Download
Conference Coverage
At 12 weeks, change in DAS28-CRP with upadacitinib was noninferior to (primary endpoint) and also superior to (secondary endpoint) abatacept. Upadacitinib was also associated with superior rate of clinical remission (DAS28-CRP < 2.6).

Released: August 17, 2020

Expiration: August 16, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AbbVie Inc.

Gilead Sciences, Inc.